Online Inquiry
Syngeneic Model Development
Syngeneic model, as a mouse model with a normal immune system, is an indispensable and important research tool for the non-clinical evaluation of anti-prostate cancer drugs. At Alfa Cytology, we offer a comprehensive prostate cancer syngeneic model tumor modelling service designed to replicate the intricate microenvironment of a tumor, enabling precise analysis and accelerated treatment development.
Introduction to Syngeneic Model
Syngeneic model is a widely used model in oncology research, which is a tumor model constructed by transplanting murine-derived tumor cells from in vitro passaging culture into mice of the same strain with a robust immune system. Compared with the immunodeficient mouse model, the syngeneic model uses immunocompetent inbred mice with an intact murine immune system to mimic the interaction between the tumor and the immune system, and is a powerful tool for studying the tumor microenvironment, tumor metastasis, and for evaluating drugs related to tumor immunotherapy.
Fig.1 DVL3 syngeneic tumors replicate patient disease. (Haughey, C. M., et al., 2020)
In addition, syngeneic tumor models have the advantages of being easy to establish, efficient and economical. Compared with human-derived tumor cell lines, there are fewer mouse-derived tumor cells to choose from, and on the other hand, due to the differences between the mouse and human immune systems, they cannot fully reflect the characteristics of human tumors. As a mouse model with normal immune system, the syngeneic tumor transplantation model is an indispensable and important research tool for the non-clinical evaluation of anti-tumor drugs.
Our Services
Syngeneic tumor explant models have important applications in drug screening and efficacy evaluation, as they can provide a relatively simple and controlled way to study tumor growth, metastasis, and response to therapy. At Alfa Cytology, we are dedicated to providing prostate homologous tumour explant models, as well as drug discovery, efficacy evaluation, and safety assessments services to meet our clients' research and drug development needs.
RM1 Model
Offer the development of the RM1 syngeneic prostate cancer model, utilizing the RM1 cell line derived from C57BL/6 mice. This model enables the formation of tumors in C57BL/6 mice through either subcutaneous or orthotopic implantation, providing a reliable platform for researchers to study prostate cancer progression, test new therapies, and investigate immune responses in a genetically matched environment.
MyC-CaP Model
Offering the development of the MyC-CaP syngeneic prostate cancer model, we utilize cells derived from the TRAMP transgenic prostate cancer mouse model. MyC-CaP cells express the androgen receptor and are androgen-sensitive, making this model ideal for studying androgen-dependent prostate cancer progression and for evaluating therapies targeting the androgen receptor pathway.
Case Study
RM-1 Syngeneic Prostate Cancer Model
Our established RM-1/C57BL/6 syngeneic model uses RM-1 cells in C57BL/6 mice to maintain the natural immune dialogue between host and tumor. It serves as a highly efficient tool for testing immunotherapies and performing rapid efficacy screens for both chemotherapy and targeted drugs.
- Model Information
Cell Line: RM-1 cell lines
Age: 4-6 weeks
Weight: 16-20 g
Species: C57BL/6 mice
Sex: Male
Fig. 2 Construction process of RM-1 syngeneic prostate cancer model
Our RM-1 cell lines are rigorously characterized and sterility-tested to guarantee viability and phenotypic stability. Following subcutaneous inoculation into the flank of C57BL/6 mice, tumor growth is accurately tracked via Vernier caliper measurements.
- Evaluation of RM-1 Syngeneic Prostate Cancer Models
Following subcutaneous inoculation, survival tracking was monitored continuously (Figure 3). To assess metastatic progression, systemic necropsies and histopathological evaluations were performed on moribund mice (Figure 4).
Fig. 3 Survival analysis of mice in RM-1/C57BL/6 syngeneic model
Fig. 4 Representative H&E staining of tumor metastasis
At Alfa Cytology, we are committed to providing you with a comprehensive and efficient prostate cancer tumor model development service to support your research and drug development needs. If you are interested in our services, please don't hesitate to contact us for further information and pricing details.
Reference
- Haughey, C. M., et al. Investigating Radiotherapy Response in a Novel Syngeneic Model of Prostate Cancer. Cancers. 2020, 12(10): 2804.
For research use only.